Evidence map›Paper›PMID 36474299›Full record

ArticleBMC research notes2022

Antibody screening data of human midgestation liver cells with a focus on hematopoietic, liver sinusoidal endothelial, and hepatoblast cell-populations.

Marcus O Muench, Christopher Nosworthy

Open access · goldAbstract read
In one paragraph

Article in BMC research notes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Marcus O MuenchVitalant Research Institute, 360 Spear Street, Suite 200, 94105, San Francisco, CA, USA. mmuench@vitalant.org.ORCID http://orcid.org/0000-0001-8946-6605
Christopher NosworthyVitalant Research Institute, 360 Spear Street, Suite 200, 94105, San Francisco, CA, USA.
Pacific Research Institute · USUniversity of California, San Francisco · US

Funding

California Institute of Regenerative Medicine DISC1-08855California Institute of Regenerative Medicine EDUC2-08400
6 · The paper itself

Abstract

objectivesCell-surface antigen screening was performed on human fetal liver cells using flow cytometry. The goal was to provide proteomic expression data on a number of human fetal liver cell populations that can inform studies on developmental hepatology and hematology. DATA DESCRIPTION: A 21 weeks' gestation liver was depleted of erythrocytes prior to antibody staining. Screening was performed using phycoerythrin-labelled antibodies against 332 antigens. In addition to these antibodies, all samples were stained for CD14, CD45, CD235a, and CD326 (epithelial cell adhesion molecule - EpCAM). Subpopulations of fetal liver cells were identified using the co-stained antigens. Hematopoietic cells were identified by their expression of CD45 and CD235a; non-hematopoietic cells were further subdivided based on CD14 and CD326 expression. CD326

Indexed as

Endothelial CellsProteomicsHumansLiverAntigensBlood CellsEndothelial CellsFetusFlow cytometryHepatologyHumanLeukocyte Common AntigensLiver

Identifiers

PMID36474299
PMCPMC9724407
OpenAlexW4311579375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.